Very recently, the involvement of TMEJ has been implicated in the development and metastasis of KRAS mutated pancreatic cancer (22) and its expression has been associated with a better response to immunotherapy in a subset of bladder cancer patients (23). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.